title: EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
abstract: OBJECTIVE
  To formulate EULAR recommendations for the management of early arthritis.
  
  
  METHODS
  In accordance with EULAR's "standardised operating procedures", the task force pursued an evidence based approach and an approach based on expert opinion. A steering group comprised of 14 rheumatologists representing 10 European countries. The group defined the focus of the process, the target population, and formulated an operational definition of "management". Each participant was invited to propose issues of interest regarding the management of early arthritis or early rheumatoid arthritis. Fifteen issues for further research were selected by use of a modified Delphi technique. A systematic literature search was carried out. Evidence was categorised according to usual guidelines. A set of draft recommendations was proposed on the basis of the research questions and the results of the literature search.. The strength of the recommendations was based on the category of evidence and expert opinion.
  
  
  RESULTS
  15 research questions, covering the entire spectrum of "management of early arthritis", were formulated for further research; and 284 studies were identified and evaluated. Twelve recommendations for the management of early arthritis were selected and presented with short sentences. The selected statements included recognition of arthritis, referral, diagnosis, prognosis, classification, and treatment of early arthritis (information, education, non-pharmacological interventions, pharmacological treatments, and monitoring of the disease process). On the basis of expert opinion, 11 items were identified as being important for future research.
  
  
  CONCLUSIONS
  12 key recommendations for the management of early arthritis or early rheumatoid arthritis were developed, based on evidence in the literature and expert consensus.
authors.affiliation: Immuno-Rhumatologie, Lapeyronie Hosp, Montpellier, France. b-combe@chu-montpellier.fr
authors.forename: B
authors.initials: B
authors.lastname: Combe
authors.forename: R
authors.initials: R
authors.lastname: Landewe
authors.forename: C
authors.initials: C
authors.lastname: Lukas
authors.forename: H D
authors.initials: HD
authors.lastname: Bolosiu
authors.forename: F
authors.initials: F
authors.lastname: Breedveld
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: G
authors.initials: G
authors.lastname: Ferraccioli
authors.forename: J M W
authors.initials: JM
authors.lastname: Hazes
authors.forename: L
authors.initials: L
authors.lastname: Klareskog
authors.forename: K
authors.initials: K
authors.lastname: Machold
authors.forename: E
authors.initials: E
authors.lastname: Martin-Mola
authors.forename: H
authors.initials: H
authors.lastname: Nielsen
authors.forename: A
authors.initials: A
authors.lastname: Silman
authors.forename: J
authors.initials: J
authors.lastname: Smolen
authors.forename: H
authors.initials: H
authors.lastname: Yazici
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001168:Arthritis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005060:Europe; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D006304:Health Status; D006801:Humans; D007596:Joints / Q000473:pathology; D012017:Referral and Consultation; D012219:Rheumatology
chemical_list: D018501:Antirheumatic Agents